The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for blockbuster treatments and impressive returns is undeniable, the linked risks are also consi